Venus Medtech (Hangzhou) Inc. (2500.HK) HKSE
Currency In HKD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In HKD
Address
No. 88, Jiangling Road
Hangzhou, 31005
China
Phone
86 57 1877 72180
Website
Sector
Healthcare
Industry
Medical - Devices
Employees
691
First IPO Date
December 10, 2019
| Name | Title | Pay | Year Born |
| Liqiao Ma | Executive Director | 2.04M | 1985 |
| Meirong Liu | VP, Chief Operation Officer & Executive Director | 2.96M | 1976 |
| Hou-Sen Lim MEng. | GM & Executive Director | 3.32M | 1975 |
| Shakeel Osman | Head of International Congenital Heart Disease Business | 0 | N/A |
| Renzheng Ma | VP & Chief Technology Officer | 0 | 1976 |
| Chui Mei Yip | Company Secretary | 0 | N/A |
| Bing Zhu | Chief Financial Officer | 0 | 1965 |
| Amir Gross | Head of Venus Global Heart Valve Innovation Center | 0 | N/A |
| Christopher Lee Richardson | Head of U.S. Operations | 0 | 1962 |
| Wai Chiu Wong | Company Secretary | 0 | 1956 |
| Yan Xiao | Secretary of the Board | 0 | 1983 |
| Zhu Bing | Chief Financial Officer | 0 | 1965 |
| Joyce Heo | Director of Sales | 0 | N/A |
Venus Medtech (Hangzhou) Inc. specializes in the global development and commercialization of catheter-based cardiac valve solutions, operating across Mainland China and international markets. Its leading product, VenusA-Valve, is a transcatheter aortic valve replacement (TAVR) designed for treating severe aortic stenosis. Another significant offering, VenusP-Valve, functions as a transcatheter pulmonary valve system addressing dysfunction of the right ventricular outflow tract. The company also provides V8/TAV8 balloon aortic valvuloplasty catheter systems. Furthermore, TriGUARD3 is a cerebral embolic protection device, vital for minimizing brain damage and preventing cerebral embolism during TAVR and other structural heart procedures. In its pipeline, Venus Medtech is advancing TAVR candidates VenusA-Plus and VenusA-Pilot, alongside transcatheter mitral and tricuspid valve replacement products. Other developmental initiatives include the Liwen RF ablation system for hypertrophic cardiomyopathy and renal denervation technology to manage hypertension. Established in 2009, Venus Medtech maintains its corporate headquarters in Hangzhou, People's Republic of China.